{
  "title": "Paper_709",
  "abstract": "pmc Curr Issues Mol Biol Curr Issues Mol Biol 4181 cimb cimb Current Issues in Molecular Biology 1467-3037 1467-3045 Multidisciplinary Digital Publishing Institute  (MDPI) PMC12468541 PMC12468541.1 12468541 12468541 41020871 10.3390/cimb47090749 cimb-47-00749 1 Brief Report Valproic Acid as a Histone Deacetylase Inhibitor Induces ABCB1 ABCB5 Luna-Palencia Gabriela Rebeca 1 Correa-Basurto José 2 Vásquez-Moctezuma Ismael 3 * Huang Ru Chih C. Academic Editor 1 galuna@cinvestav.mx 2 jcorreab@ipn.mx 3 * ivasquezm@ipn.mx 11 9 2025 9 2025 47 9 497442 749 23 7 2025 07 9 2025 09 9 2025 11 09 2025 27 09 2025 01 10 2025 © 2025 by the authors. 2025 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ Histone deacetylase inhibitors (HDACis) induce the expression of multidrug resistance (MDR) pumps and can even display the MDR phenotype in cell lines. This is the first report to include the profiles of ATP-binding cassette (ABC) transporters in intrinsically expressed HeLa cells as well as those acquired due to a 5 mM valproic acid (VPA) treatment. Expression of ABC transporters related to the MDR phenotype was analyzed by RT-PCR in untreated HeLa cells and HeLa cells treated with 5 mM VPA. The ABCB5 protein was identified in HeLa cells by immunocytochemistry. HeLa cell treatment with 5 mM VPA increased ABCB1 ABCB5 ABCB5 ABCB1 ABCB5 ABCB5 MDR1 valproic acid epigenetic drugs anticancer drugs CONACYT CB-132353 PIFI-SIP-COFAA/IPN 2015/0322/0944/0946 This study was supported by grants from CONACYT (CB-132353) and PIFI-SIP-COFAA/IPN (2015/0322/0944/0946). Scholarships were provided by CONACYT. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes 1. Introduction It was discovered that daunomycin can be extruded by an active transport mechanism in resistant Ehrlich ascites tumor cells [ 1 2 Failure in the use of diverse therapies for cancer, rheumatic arthritis, bacterial infections, and epilepsy has been attributed to MDR. In cancer, MDR is an intrinsic or acquired mechanism whereby cells show resistance to one drug, which is accompanied by resistance to other structurally different chemotherapeutic drugs. Intrinsic resistance is a pre-existing mechanism that decreases the initial efficacy of anticancer treatment and is independent of any prior exposure to cytotoxic drugs, whereas acquired resistance is induced by repeated drug administrations. The MDR phenotype is mainly characterized by the overexpression of ABC drug transporter proteins, which facilitate the efflux of cytotoxic agents from the cell via an ATP-dependent process, resulting in a lower intracellular accumulation of anticancer drugs. ABC transporters are not only expressed by cancer cells; they are also located in the cell membrane of many normal tissues to protect the cell from cytotoxic agents [ 3 4 ABCC13 5 6 5 7 5 8 9 8 ABCB5 ABCB5 5 10 ABCB5 5 11 ABCB5 ABCB5 12 ABCB5 + 13 14 ABCB5 15 The ABC transporter family’s efflux pumps are subject to epigenetic gene regulation [ 16 17 18 19 20 21 22 23 In this work, we explored the intrinsic and 5 mM VPA-induced expression of ABC proteins related to drug resistance in HeLa cell cultures at the mRNA and protein levels. Furthermore, we determined if VPA-induced ABCB5 influences the acquisition of the MDR phenotype using DOX as a known substrate of the ABCB5 protein, which confers chemotherapy resistance in melanoma. 2. Materials and Methods 2.1. Chemical Reagents VPA and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma Chemical Co., (St. Louis, MO, USA), while DOX was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 2.2. Cell Culture The HeLa cell line from cervical cancer CCL-2 was kindly donated by Dr. Saúl Villa Treviño, a researcher at the CINVESTAV, and was cultured in Dulbecco’s modified Eagle’s medium (DMEM Glutamax, Gibco, Life-Technologies, Invitrogen, Grand Island, NE, USA) supplemented with 10% ( v v 2 2.3. Total RNA Extraction, Reverse Transcription, and Polymerase Chain Reaction to Evaluate the Expression of Genes Related to Multidrug Resistance Mechanisms Total RNA was isolated with TRIzol (Invitrogen, Grand Island, NE, USA) according to the manufacturer’s instructions. RNA integrity was electrophoretically verified with 1% agarose gel by ethidium bromide staining, and RNA purity was obtained to be ˃1.8 using the OD 260 280 50 24 Table 1 2.4. ABCB5 Sequencing To verify the identity of the ABCB5 fragment, the 85 bp band was cloned into competent E. coli ABCB5 2.5. ABCB5 Immunofluorescence Staining HeLa cells (15 × 10 3 2.6. Trypan-Blue Exclusion Method HeLa cells (5 × 10 3 v v 25 2.7. In Vitro Cytotoxicity Assay of DOX for VPA Sensitization of HeLa Cells HeLa cells (1 × 10 3 24 2.8. Statistical Analysis Data were expressed as the mean ± SD. A two-way ANOVA followed by Sidak’s multiple comparisons test was performed, using GraphPad Prism version 8.4.3 for Windows, GraphPad Software, La Jolla, CA, USA ( www.graphpad.com 3. Results 3.1. The Epigenetic Effect of 5 mM Valproic Acid Changes the Expression of the ABCB1 and ABCB5 Pumps in HeLa Cells To examine the expression of drug resistance pumps when treated with the epigenetic agent, cDNA from HeLa cells incubated with 5 mM VPA was amplified by PCR, with the results showing that these cells increase the expression of ABCB1 ABCB5 ABCB5 Figure 1 ABCB1 ABCB5 3.2. Sequencing of the ABCB5 Fragment Obtained by RT-PCR Demonstrates That It Is an Amplicon of ABCB5 cDNA To confirm that the 85 bp sequence amplified using primers for ABCB5 ABCB5 Figure 1 3.3. It Is Possible to Detect the ABCB5 Pump Using a Specific Monoclonal Antibody in HeLa Cells Treated with 5 mM Valproic Acid Given the importance of ABCB5 in human cancer biology, we explored the expression of this pump at the protein level in HeLa cells treated with close the IC 50 Figure 2 ABCB5 3.4. The Presence of the ABCB5 Pump in HeLa Cells Is Not Sufficient to Confer an Advantage Against Treatment with DOX In this work, despite the expression of ABCB5 ABCB1 Figure 3 50 Figure 4 4. Discussion Valproic acid has been shown to induce P-glycoprotein in human tumor cell lines and in rat liver [ 26 27 ABCB1 ABCB1 28 + 29 In melanoma, subpopulations of ABCB5-expressing cells increase their tumorigenicity and display properties similar to those of cancer stem cells (CSCs) [ 30 20 21 31 11 32 The anticancer effect of VPA is primarily attributed to the inhibition of HDACs [ 14 33 p21 33 ABCB1 ABCB5 14 50 Figure 4 34 ABCB5 35 36 37 38 Human ABC transporters are located in the plasma membrane and have transport functions [ 39 Figure 2 7 11 Based on the results of this work, we propose that HDACis, like VPA, can sensitize cancer cells, as the induced expression of certain ABC proteins does not confer functionality. Additionally, treatment with these epigenetic drugs may cause cells to express novel targets, such as ABCB5, which could be advantageous in biological therapies using therapeutic monoclonal antibodies. Acknowledgments The authors thank Leticia Alemán-Lazarini from CINVESTAV for her technical and scientific support in the recording and analysis of confocal microscopy. Disclaimer/Publisher’s Note: Author Contributions Conceptualization, I.V.-M. and G.R.L.-P.; methodology, G.R.L.-P. and J.C.-B.; formal analysis, G.R.L.-P. and I.V.-M.; investigation, G.R.L.-P.; resources, I.V.-M.; data curation, G.R.L.-P. and J.C.-B.; writing—original draft preparation, G.R.L.-P., I.V.-M. and J.C.-B.; writing—review and editing, G.R.L.-P.; supervision, I.V.-M.; project administration, I.V.-M. All authors have read and agreed to the published version of the manuscript. Conflicts of Interest The authors declare no conflicts of interest. References 1. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells Biochim. Biophys. Acta 1973 323 466 483 10.1016/0005-2736(73)90191-0 4796512 2. Juliano R.L. Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 1976 455 152 162 10.1016/0005-2736(76)90160-7 990323 3. Wang X. Zhang H. Chen X. Drug resistance and combating drug resistance in cancer Cancer Drug Resist. 2019 2 141 160 10.20517/cdr.2019.10 34322663 PMC8315569 4. Schinkel A.H. Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview Adv. Drug. Deliv. Rev. 2003 55 3 29 10.1016/S0169-409X(02)00169-2 12535572 5. Moitra K. Scally M. McGee K. Lancaster G. Gold B. Dean M. Molecular Evolutionary Analysis of ABCB5: The Ancestral Gene Is a Full Transporter with Potentially Deleterious Single Nucleotide Polymorphims PLoS ONE 2011 6 e16318 10.1371/journal.pone.0016318 21298007 PMC3029322 6. Yabuuchi H. Takayanagi S.I. Yoshinaga K. Taniguchi N. Aburatani H. Ishikawa T. ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver Biochem. Biophys. Res. Commun. 2002 299 410 417 10.1016/S0006-291X(02)02658-X 12445816 7. Duvivier L. Gillet J.P. Deciphering the roles of ABCB5 in normal and cancer cells Trends Cancer 2022 8 795 798 10.1016/j.trecan.2022.07.001 35907754 8. Wang J.Q. Yang Y. Cai C.Y. Teng Q.X. Cui Q. Lin J. Assaraf Y.G. Chen Z.S. Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance Drug Resist. Updates 2021 54 100743 10.1016/j.drup.2021.100743 33513557 9. Löscher W. How to explain multidrug resistance in epilepsy? Epilepsy Curr. 2005 5 107 112 10.1111/j.1535-7511.2005.05311.x 16145617 PMC1198632 10. Wilson B.J. Schatton T. Zhan Q. Gasser M. Ma J. Saab K.R. Schanche R. Waaga-Gasser A.M. Gold J.S. Huang Q. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients Cancer Res. 2011 71 5307 5316 10.1158/0008-5472.CAN-11-0221 21652540 PMC3395026 11. Díaz-Anaya A.M. Gerard L. Albert M. Gaussin J.F. Boonen M. Gillet J.P. The β Isoform of Human ATP-Binding Cassette B5 Transporter, ABCB5β, Localizes to the Endoplasmic Reticulum Int. J. Mol. Sci. 2023 24 15847 10.3390/ijms242115847 37958830 PMC10649157 12. Sana G. Madigan J.P. Gartner J.J. Fourrez M. Lin J. Qutob N. Narayan J. Shukla S. Ambudkar S.V. Xia D. Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities J. Investig. Dermatol. 2019 139 1985 1992 10.1016/j.jid.2019.01.036 30905807 PMC6708748 13. Yin Q. Shi X. Lan S. Jin H. Wu D. Effect of melanoma stem cells on melanoma metastasis Oncol. Lett. 2021 22 566 10.3892/ol.2021.12827 34113394 PMC8185701 14. Frank N.Y. Margaryan A. Huang Y. Schatton T. Waaga-Gasser A.M. Gasser M. Sayegh M.H. Sadee W. Frank M.H. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma Cancer Res. 2005 65 4320 4333 10.1158/0008-5472.can-04-3327 15899824 15. Yao J. Yao X. Tian T. Fu X. Wang W. Li S. Shi T. Suo A. Ruan Z. Guo H. ABCB5-ZEB1 Axis Promotes Invasion and Metastasis in Breast Cancer Cells Oncol. Res. 2017 5 305 316 10.3727/096504016X14734149559061 PMC7841086 28281973 16. Chen Z. Shi T. Zhang L. Zhu P. Deng M. Huang C. Hu T. Jiang L. Li J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade Cancer Lett. 2016 370 153 164 10.1016/j.canlet.2015.10.010 26499806 17. Fantin V.R. Richon V.M. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications Clin. Cancer Res. 2007 13 7237 7242 10.1158/1078-0432.ccr-07-2114 18094401 18. Emran T.B. Shahriar A. Mahmud A.R. Rahman T. Abir M.H. Siddiquee M.F. Ahmed H. Rahman N. Nainu F. Wahyudin E. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches Front. Oncol. 2022 12 891652 10.3389/fonc.2022.891652 35814435 PMC9262248 19. Muriithi W. Macharia L.W. Heming C.P. Echevarria J.L. Nyachieo A. Filho P.N. Neto V.M. ABC transporters and the hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance Cancer Biol. Med. 2020 17 253 269 10.20892/j.issn.2095-3941.2019.0284 32587767 PMC7309456 20. Göttlicher M. Minucci S. Zhu P. Kramer O.H. Schimpf A. Giavara S. Sleeman J.P. LoCoco F. Nervi C. Pelicci P.G. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J. 2001 20 6969 6978 10.1093/emboj/20.24.6969 11742974 PMC125788 21. Phiel C.J. Zhang F. Huang E.Y. Guenther M.G. Lazar M.A. Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J. Biol. Chem. 2001 276 36734 36741 10.1074/jbc.m101287200 11473107 22. Khan N. Jeffers M. Kumar S. Hackett C. Boldog F. Khramtsov N. Qian X. Mills E. Berghs S.C. Carey N. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem. J. 2008 409 581 589 10.1042/BJ20070779 17868033 23. Adhikari S. Bhattacharya A. Adhikary S. Singh V. Gadad S.S. Roy S. Das C. The paradigm of drug resistance in cancer: An epigenetic perspective Biosci. Rep. 2022 42 BSR20211812 10.1042/BSR20211812 35438143 PMC9069444 24. Luna-Palencia G.R. Martinez-Ramos F. Vásquez-Moctezuma I. Fragoso-Vazquez M.J. Mendieta-Wejebe J.E. Padilla-Martínez I.I. Sixto-Lopez Y. Mendez-Luna D. Trujillo-Ferrara J. Meraz-Rios M.A. Three amino acid derivatives of valproic acid: Design, synthesis, theoretical and experimental evaluation as anticancer agents Anti-Cancer Agents Med. Chem. 2014 14 984 993 10.2174/1871520614666140127113218 24476311 25. Roth V. 2006 Doubling Time Computing Available online: https://www.doubling-time.com/compute.php (accessed on 3 February 2025) 26. Eyal S. Lamb J.G. Smith-Yockman M. Yagen B. Fibach E. Altschuler Y. White H.S. Bialer M. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver Br. J. Pharmacol. 2006 149 250 260 10.1038/sj.bjp.0706830 16894351 PMC2014277 27. Benderra Z. Faussat A.M. Sayada L. Perrot J.Y. Chaoui D. Marie J.P. Legrand O. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias Clin. Cancer. Res. 2004 10 7896 7902 10.1158/1078-0432.CCR-04-0795 15585622 28. Boyer T. Gonzales F. Barthélémy A. Marceau-Renaut A. Peyrouze P. Guihard S. Lepelley P. Plesa A. Nibourel O. Delattre C. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study Cancers 2019 11 1323 10.3390/cancers11091323 31500210 PMC6770064 29. Sucha S. Sorf A. Svoren M. Vagiannis D. Ahmed F. Visek B. Ceckova M. ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia Biomed. Pharmacother. 2022 150 112962 10.1016/j.biopha.2022.112962 35462331 30. Chartrain M. Riond J. Stennevin A. Vandenberghe I. Gomes B. Lamant L. Meyer N. Gairin J.E. Guilbaud N. Annereau J.P. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells PLoS ONE 2012 7 e36762 10.1371/journal.pone.0036762 22675422 PMC3360047 31. Chen K. Huang Y.H. Chen J.L. Understanding and targeting cancer stem cells: Therapeutic implications and challenges Acta Pharmacol. Sin. 2013 34 732 740 10.1038/aps.2013.27 23685952 PMC3674516 32. Gerard L. Duvivier L. Fourrez M. Salazar P. Sprimont L. Xia D. Ambudkar S.V. Gottesman M.M. Gillet J.P. Identification of two novel heterodimeric ABC transporters in melanoma: ABCB5β/B6 and ABCB5β/B9 J. Biol. Chem. 2024 300 105594 10.1016/j.jbc.2023.105594 38145744 PMC10828454 33. Luna-Palencia G.R. Correa-Basurto J. Trujillo-Ferrara J. Meraz-Ríos M.A. Vásquez- Moctezuma I. Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells Curr. Mol. Pharmacol. 2021 14 570 578 10.2174/1874467213666200730113828 32744980 34. Kim M.S. Blake M. Baek J.H. Kohlhagen G. Pommier Y. Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res. 2003 63 7291 7300 14612526 35. Arce C. Pérez-Plasencia C. González-Fierro A. de la Cruz-Hernández E. Revilla-Vázquez A. Chávez-Blanco A. Trejo-Becerril C. Pérez-Cárdenas E. Taja-Chayeb L. Bargallo E. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer PLoS ONE 2006 1 e98 10.1371/journal.pone.0000098 17183730 PMC1762324 36. Wang Y. Kuramitsu Y. Kitagawa T. Tokuda K. Baron B. Akada J. Nakamura K. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX Target Oncol. 2015 10 575 581 10.1007/s11523-015-0370-0 25940934 37. Ji M. Lee E.J. Kim K.B. Kim Y. Sung R. Lee S.J. Kim D.S. Park S.M. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells Oncol. Rep. 2015 33 2299 2308 10.3892/or.2015.3879 25813246 38. Li H. Zhang Z. Gao C. Wu S. Duan Q. Wu H. Wang C. Shen Q. Yin T. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells Cell Biosci. 2019 9 50 Erratum in Cell Biosci. 2023 13 10.1186/s13578-019-0312-0 31244991 PMC6582499 39. Moore J.M. Bell E.L. Hughes R.O. Garfield A.S. ABC transporters: Human disease and pharmacotherapeutic potential Trends Mol. Med. 2023 29 152 172 10.1016/j.molmed.2022.11.001 36503994 Figure 1 RT-PCR of some genes related to multidrug resistance mechanisms ( A B Figure 2 Protein sequence detected by Novus ABCB5 monoclonal antibody and its comparison to variants 1 and 2. The immunogen comprises 194 amino acids ( A B Figure 3 Living HeLa cells per well treated with 5 mM VPA for 24, 48, and 72 h, showing the equation (R 2 p Figure 4 Effect of pretreatment and coincubation of 5 mM VPA with different concentrations of DOX on HeLa cell survival determined by MTT assay. Results are expressed as the mean ± SD for n = 3. * p p cimb-47-00749-t001_Table 1 Table 1 Oligonucleotides used to evaluate the expression of genes related to multidrug resistance mechanisms.  Gene (Protein) Forward Reverse Size (bp) 1 ABCC1 5′-gACAgAgATTggCgAgAAg-3′ 5′-ATgTCAgCgTTggAgTACAC-3′ 90 2 ABCC2 5′-AgAgAAgCTgACCATCATCC-3′ 5′-ACCAggATCTTggATTTCCg-3′ 255 3 ABCC3 5′-TgCAggTgACATTTgCTCTg-3′ 5′-AgCgCACAgAATAATTCCgg-3′ 192 4 ABCC4 5′-CTgAgAATgACgCACAgAAg-3′ 5′-TATgggCTggATTACTTTgg-3′ 122 5 ABCC5 5′-TCCgCCACTgTAAgATTCTg-3′ 5′-CATggCATAgAATCgggAAC-3′ 242 6 ABCC6 5′-TgCAgTACAAgTgTgCTgAC-3′ 5′-CTgTAAAACAggCCCTTCTg-3′ 313 7 ABCC10 5′-gAggTgATTACATCCATggg-3′ 5′-ACTgTCTTgTTggCAAAgCg-3′ 212 8 ABCG2 5′-AAggAgATCAgCTACACCAC-3′ 5′-CACTgCTgAAACACTggTTg-3′ 232 9 ABCB1 5′-TACTTggTggCACATAAACTC-3′ 5′-gCATAgTCAggAgCAAATgA-3′ 113 10  ABCB5 5′-AggACAAgTgCTgTTTgATg-3′ 5′-CTCTTgAggAACgATTgCTA-3′ 85 11  GAPDH 5′-gTATgACAACAgCCTCAAgAT-3′ 5′-gTCCTTCCACgATACCAAAg-3′ 104 ",
  "metadata": {
    "Title of this paper": "ABC transporters: Human disease and pharmacotherapeutic potential",
    "Journal it was published in:": "Current Issues in Molecular Biology",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468541/"
  }
}